Nautilus Biotechnology (NAUT) Set to Post Quarterly Earnings on Tuesday

Nautilus Biotechnology (NASDAQ:NAUT) is projected to release its Q3 2026 results before the market opens on Tuesday, October 27th. Analysts expect Nautilus Biotechnology to announce earnings of ($0.14) per share and revenue of $0.21 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 8:30 AM ET.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its quarterly earnings results on Monday, July 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.03. The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.10 million. On average, analysts expect Nautilus Biotechnology to post ($0.52) EPS for the current fiscal year and ($0.53) EPS for the next fiscal year.

Nautilus Biotechnology Price Performance

NASDAQ:NAUT opened at $2.63 on Tuesday. Nautilus Biotechnology has a 12-month low of $0.84 and a 12-month high of $4.31. The firm has a market capitalization of $334.67 million, a P/E ratio of -5.84 and a beta of 0.73. The business has a 50 day simple moving average of $1.24 and a 200 day simple moving average of $1.91.

Wall Street Analysts Forecast Growth

NAUT has been the topic of several analyst reports. Leerink Partners started coverage on Nautilus Biotechnology in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $4.00 target price on the stock. Roth Capital initiated coverage on Nautilus Biotechnology in a research note on Tuesday, September 29th. They issued a “buy” rating and a $3.50 target price on the stock. Zacks Research raised shares of Nautilus Biotechnology to a “hold” rating in a report on Wednesday, September 30th. Finally, Weiss Ratings lowered shares of Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $3.83.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc is a life sciences technology company developing tools for large-scale protein analysis. Its goal is to enable more comprehensive, sensitive and efficient study of the proteome, the full set of proteins expressed by a biological system, to support research in drug discovery, disease biology and translational science.

The company’s primary offering is the Nautilus Proteome Analysis Platform, which combines a proprietary analytical instrument, consumables and software.